The primary outcome was the change (∆) in LF:HF in response to Ang-II challenge, before and after vitamin D 3 supplementation. Values are presented as mean±SE. CAT differences between pre-vitamin D 3 supplementation and post-vitamin D 3 supplementation were tested using nonparametric Student t test methods. Repeated measures ANOVA was used to assess whether 25-hydroxy and 1,25-dihydroxy vitamin D levels on each study day were significant factors in association with differences in CAT responses to Ang-II challenge between subjects. Changes in 25-hydroxy and 1,25-dihydroxy vitamin D levels from pre-vitamin D 3 supplementation to post-vitamin D 3 supplementation study days were assessed independently and together as a multiplicative variable to determine the magnitude of the association between the individual vitamin D responses to supplementation and changes in Ang-II challenge responses within each subject. Greenhouse−Geisser corrections were made where appropriate. The following covariates were included: age, race, sex, baseline estimated glomerular filtration rate, and baseline heart rate. On the basis of the work of Kontopoulos et al, 8 a sample size of 15 was calculated to achieve 90% power to detect a 1-SD increase in baseline measures of HF before and after vitamin D 3 supplementation. All statistical analyses were performed using SPSS (version 19; IBM), with 2-tailed significance levels of 0.05.
Levels Table) .
Compared with presupplementation, vitamin D 3 supplementation was associated with stabilization of the LF:HF response to Ang-II (Table) . Before supplementation, LF:HF fluctuated in response to Ang-II and during recovery (Figure) . In comparison, after vitamin D 3 supplementation, subjects displayed significantly decreased LF:HF in response to graded Ang-II infusion and during recovery (∆LF:HF: 3 ng/kg per min Ang-II, −0.21±0.14, P=0.04; 6 ng/kg per min Ang-II, −0.21±0.11, P=0.03; recovery, −0.14±0.07, P=0.035 versus presupplementation response; Figure) , largely because of a decline in measures of LF, most notably during recovery (∆LF [nu]: recovery, P=0.014 versus presupplementation response). Blood pressure and circulating RAS components responded to Ang-II as expected, although no differences in any parameters were observed before and after vitamin D 3 supplementation.
Secondary analyses with repeated measures ANOVA showed that intraindividual differences in 1,25-dihydroxy vitamin D levels appeared to account for the observed divergence in CAT responses over the 3 time points during and after Ang-II challenge (3 ng/kg per min, 6 ng/kg per min; recovery). Before supplementation, individuals with levels of 1,25-dihydroxy vitamin D below the median value of 105 pmol/L demonstrated a decline in parasympathetic tone throughout Ang-II challenge and recovery, whereas those with 1,25-dihydroxy vitamin D levels above 105 pmol/L showed a favorable and graded increase in cardioprotective parasympathetic activity in response to increasing doses of Ang-II throughout the study irrespective of 25-hydroxy vitamin D levels. After 4 weeks of oral vitamin D 3 supplementation, 1,25-dihydroxy vitamin D levels above the postsupplementation median value (120 pmol/L) remained strongly associated with the same significant trend of steadily increasing parasympathetic activity in response to Ang-II challenge and recovery (HF [nu]: F=6.96; df=1; P=0.039)
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In a post hoc analysis, baroreflex sensitivity was analyzed in a subgroup of subjects (n=5; 1 woman and 4 men) with adequate baroreflex sensitivity measurement as a secondary measure of parasympathetic activity. Although not statistically significant, there was a trend toward increased baroreflex sensitivity after vitamin D 3 supplementation as throughout Ang-II challenge, baroreflex sensitivity followed the same trend as measured HF (Table) .
To the best of our knowledge, this is the first study investigating the effect of vitamin D supplementation on CAT, a potentially modifiable marker of cardiovascular risk, in humans with CKD. Our key findings are as follows: (1) vitamin D supplementation was associated with favorable changes in LF:HF during and after a physiological stressor in subjects with IgA nephropathy and early CKD and (2) 1,25-dihydroxy, rather than 25-hydroxy vitamin D, levels were associated with a graded increase in cardioprotective parasympathetic activity in response to increasing doses of Ang-II. A decrease in parasympathetic activity contributes to SCD risk, 7 and previous studies have suggested that 1,25-dihydroxy vitamin D may be the most robust marker of cardiovascular risk in the CKD population. 3, 4 Together with our present findings, these observations suggest that vitamin D supplementation, with the specific goal of increasing 1,25-dihydroxy vitamin D levels and improving overall cardiac autonomic activity, may be a potential preventive cardiovascular therapy in this high-risk population. Interestingly, we did not find that vitamin D 3 supplementation was associated with a change in resting (baseline) heart rate variability parameters. Our findings suggest that increasing vitamin D levels are associated with improved modulation of CAT in response to an Ang-II stressor, perhaps highlighting an important interaction between vitamin D and cardiovascular risk specific to populations with increased RAS activity, such as CKD.
Previous studies have suggested that vitamin D, and specifically 1,25-dihydroxy vitamin D, affects the cardiac autonomic system in several ways, including enhancement of electrophysiological β-adrenergic signaling between cardiac myocytes. 5 1,25-dihydroxy vitamin D crosses the blood-brain barrier and therefore may have physiological implications at the molecular level within the nervous system. 5 In support of our findings, a large cross-sectional study of patients with end-stage kidney disease on hemodialysis reported a positive association between 25-hydroxyvitamin D levels and allcause and cardiovascular mortality, but that this relationship was no longer observed in patients treated with analogues of 1,25-dihydroxy vitamin D, 4 suggesting that cardioprotection is mediated by the activated form of vitamin D. Similarly, Dobnig et al 1 reported that serum levels of 1,25-dihydroxy vitamin D were independently associated with cardiovascular mortality in a large cohort of patients undergoing coronary angiogram. Our observations of an increase in cardioprotective parasympathetic activity (HF) in response to Ang-II challenge observed only in those subjects with higher levels of 1,25-dihydroxy vitamin D support the findings from these larger studies.
This study has limitations. In humans, vitamin D metabolism is related to that of other minerals and hormones that might influence cardiovascular risk, including parathyroid hormone. 2 Inclusion of these other variables did not significantly change our results, perhaps because of the narrow and clinically insignificant ranges observed in the participants of 
